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Abstract Vascular endothelial growth factor-C (VEGF-C) acts primarily on endothelial cells, but
also on non-vascular targets, for example in the CNS and immune system. Here we describe a
novel, unique VEGF-C form in the human reproductive system produced via cleavage by kallikrein-
related peptidase 3 (KLK3), aka prostate-specific antigen (PSA). KLK3 activated VEGF-C specifically
and efficiently through cleavage at a novel N-terminal site. We detected VEGF-C in seminal plasma,
and sperm liquefaction occurred concurrently with VEGF-C activation, which was enhanced by
collagen and calcium binding EGF domains 1 (CCBE1). After plasmin and ADAMTS3, KLK3 is the
third protease shown to activate VEGF-C. Since differently activated VEGF-Cs are characterized by
successively shorter N-terminal helices, we created an even shorter hypothetical form, which
showed preferential binding to VEGFR-3. Using mass spectrometric analysis of the isolated VEGF-
C-cleaving activity from human saliva, we identified cathepsin D as a protease that can activate
VEGF-C as well as VEGF-D.
DOI: https://doi.org/10.7554/eLife.44478.001
Introduction
Vascular endothelial growth factor VEGF-A is essential for early embryonic development and for suc-
cessful implantation of the embryo into the uterus (Binder et al., 2014). VEGF-A acts in this function
on both vascular and non-vascular targets (Hannan et al., 2011). The primary function of the closely
related growth factor VEGF-C is stimulation of growth of the lymphatic vasculature (Rauniyar et al.,
2018). VEGF-C is required for ovarian follicle growth and maturation and endometrial lymphangio-
genesis (Rogers, 2008; Rutkowski et al., 2013). Unlike VEGF-A, which is secreted as an active
growth factor (Leung et al., 1989), VEGF-C is secreted as an inactive precursor (pro-VEGF-C), which
requires two proteolytic cleavages for activation (Jeltsch et al., 2014; Joukov et al., 1997). The first
C-terminal cleavage resulting in pro-VEGF-C occurs constitutively in the endoplasmic reticulum and
is mediated by proprotein convertases (Siegfried et al., 2003). The second cleavage takes place in
the extracellular environment, is highly regulated and requires the assembly of a trimeric complex
consisting of VEGF-C, the ADAMTS3 metalloproteinase and the ‘cofactor’ CCBE1 (Bui et al., 2016;
Jeltsch et al., 2014). Alternative activation by plasmin has been shown in vitro, but its significance
under physiological settings is unknown (McColl et al., 2003). VEGF-D is the closest paralog of
VEGF-C (Achen et al., 1998). Similar to VEGF-C, it is lymphangiogenic (Veikkola et al., 2001), but
appears to have a higher angiogenic potential than VEGF-C (Byzova et al., 2002; Rissanen et al.,
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2003). The proteolytic activation of VEGF-D is very similar to that of VEGF-C (Stacker et al., 1999a),
but it deploys distinct, so far unknown proteases (Bui et al., 2016).
Many kallikrein-related peptidases are highly expressed in the prostate, and some prostate-
derived cell lines, such as the immortalized human normal prostate epithelial (NPrEC) or PC-3 cells
— from which VEGF-C was originally cloned — express high amounts of VEGF-C (Grennan, 2006;
Joukov et al., 1996). In a peptide library scan, Matsumura et al. (2005) identified VEGF-C as a
potential substrate for KLK4. Based on these observations, we tested human kallikrein-related pepti-
dases for their ability to activate VEGF-C. In this study, we show that KLK3, the major protease in
human semen, is able to specifically activate VEGF-C and VEGF-D. We further show that cathepsin D
cleavage of VEGF-C results in a novel, predominantly VEGFR-3-binding form of VEGF-C, and that
cathepsin D cleavage of VEGF-D at the homologous site results in a VEGFR-2-specific (minor mature)
form of VEGF-D.
Results
VEGF-C is processed by the kallikrein-related peptidase 3 (KLK3)
We could not demonstrate robust VEGF-C activation by KLK4 as predicted by Matsumura et al.
(2005) (data not shown), but purified KLK3 cleaved pro-VEGF-C, resulting in a mature protein that
migrated at about 20 kDa in Western blotting analysis (Figure 1A, lane 2). To confirm that KLK3 was
responsible for the cleavage, we inhibited its protease activity by using the monoclonal antibody
5C7 (Stenman et al., 1999) in 2-fold molar excess (Figure 1A, lane 1 versus lane 2). We probed the
polypeptide bands resulting from the cleavage with rabbit antiserum 6 and antiserum 3/4, which
were raised against full-length and mature VEGF-C, respectively (Figure 1A and B, compare the sec-
ond lanes). Probing with antiserum 3/4, which recognizes both pro-VEGF-C and mature VEGF-C,
showed that the majority of pro-VEGF-C had been cleaved by KLK3.
eLife digest The lymphatic system is composed of networks of vessels that drain fluids from the
body’s tissues and filter it back into the blood. Growing these vessels depends on a factor known as
VEGF-C, which is released in an inactive form and must be cut by enzymes before it can work. One
enzyme that is known to activate the VEGF-C signal when the early embryo is developing is
ADAMTS3. If this signal fails to switch on this can result in a condition known as lymphedema –
whereby problems in the lymphatic system cause tissues to swell due to insufficient drainage.
However, it is unknown whether the VEGF-C signal can be activated by enzymes other than
ADAMTS3.
To investigate this Jha, Rauniyar et al. tested a specific family of proteins commonly found in the
human prostate, which have previously been predicted to act on VEGF-C. This revealed that the
lymphatic vessel growth factor can also be activated by an enzyme found in seminal fluid called
prostate specific antigen, or PSA for short. To see if enzymes in other bodily fluids could switch on
VEGF-C, different components of human saliva were separated and tested to see which could cut
inactive VEGF-C. This showed that VEGF-C could be converted to an active form by another enzyme
called cathepsin D.
Unexpectedly, Jha, Rauniyar et al. found that VEGF-C was also present in semen. For conception
to occur PSA must liquify the semen following ejaculation. It was discovered that PSA activates
VEGF-C just as the semen starts to liquify, suggesting that the lymphatic vessel growth factor might
also play an important role in reproduction. In addition to VEGF-C, both PSA and cathepsin D were
found to activate another growth factor called VEGF-D, which has an unknown role in the human
body.
VEGF-C helps the spread of tumors, and blocking the two enzymes that activate this growth
factor may be a new therapeutic approach for cancer. However, more work is needed to validate
which types of tumor, if any, use these enzymes to activate VEGF-C. In addition, understanding the
relationship between PSA and VEGF-C could help improve our knowledge of human reproduction.
DOI: https://doi.org/10.7554/eLife.44478.002
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KLK3-processed VEGF-C is biologically active
We tested the KLK3-processed VEGF-C for its biological activity in Ba/F3 cells, which had been sta-
bly transfected with VEGFR/EpoR chimeras and found that it promoted the survival of both VEGFR-
2/EpoR (Figure 1C) and VEGFR-3/EpoR cells (Figure 1D).
KLK3 activation of VEGF-C results in a unique VEGF-C species
Edman degradation of the KLK3-processed VEGF-C revealed the amino-terminal sequence NTEIL
(Figure 2—figure supplement 1). Thus, KLK3 cleaves VEGF-C between Tyr-114 and Asn-115, tar-
geting a sequence similar to most of its cleavage sites in the seminogelins, which are the primary tar-
get proteins of KLK3 (Malm et al., 2000). The KLK3-cleaved VEGF-C is three N-terminal amino acid
residues shorter than the mature VEGF-C generated by ADAMTS3 (Jeltsch et al., 2014) and 12
amino acid residues shorter than the mature VEGF-C produced by PC-3 cells (Figure 2)
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Figure 1. Kallikrein-related peptidase 3 (KLK3)/Prostate specific antigen (PSA) activates VEGF-C. (A, B) Cleavage of pro-VEGF-C by KLK3 (PSA). Pro-
VEGF-C was incubated with or without KLK3, with and without the monoclonal antibody against KLK3 (5C7). Detection of VEGF-C in Western blots
probed with antiserum 6 and 3/4, resulting in the detection of pro-VEGF-C (29/31 kDa) and activated, mature VEGF-C (21/23 kDa). The band marked by
the asterisk likely represents the N-terminal propeptide (~15 kDa) which is detected by the antiserum 6. Note that for the image shown for antiserum 6,
two different exposures of the same blot were merged (n = 3). (C, D) VEGF-C processed by KLK3 is biologically active in Ba/F3 cell assays, which
translate activation of a hybrid VEGFR/EpoR receptor into cell survival (n = 2). Error bars indicate SD.
DOI: https://doi.org/10.7554/eLife.44478.003
The following source data is available for figure 1:
Source data 1. Ba/F3 assay showing the activity of KLK3-cleaved VEGF-C.
DOI: https://doi.org/10.7554/eLife.44478.004
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(Joukov et al., 1997). We analyzed the VEGF-C amino acid sequences of 40 vertebrate species and
found that residues  7 to +1 relative to the KLK3 cleavage site and  4 to +4 relative to the
ADAMTS3 cleavage site (KFAA#AHY#N) are 100% conserved among all mammals and birds that
were included in the analysis. However, we found significant differences in this area in all fish species
analyzed (Figure 2—figure supplement 2).
Human seminal fluid contains VEGF-C
To evaluate the biological significance of VEGF-C activation by KLK3, we first analyzed the VEGF-C
content of human seminal plasma. Because of difficulties in detecting VEGF-C at low ng/ml-range
concentrations in a high-protein sample (~50 mg/ml), such as semen (Owen and Katz, 2005), we
first compared the ability of different anti-VEGF-C antibodies to detect VEGF-C (Figure 3—figure
supplement 1, Supplementary file 1). VEGF-C was detected in Western blots of sperm liquefied for
approximately 20–30 min at room temperature by using antibody sc-374628 after VEGF-C precipita-
tion with soluble forms of its receptors VEGFR-2 (VEGFR-2/Fc) and VEGFR-3 (VEGFR-3/Fc) or anti-
VEGF-C antiserum 882 (Figure 3A). The affinity of seminal plasma VEGF-C towards VEGFR-2
appeared to be much weaker than towards VEGFR-3 in the VEGF-C pull down assay (Figure 3A,
compare lanes 4 and 6). The mobilities of the VEGF-C polypeptides indicated that it is composed of
inactive pro-VEGF-C and active mature VEGF-C. Stimulation of VEGFR-3-transfected porcine aortic
endothelial (PAE) cells with seminal plasma resulted in VEGFR-3 phosphorylation (Figure 3B, com-
pare lanes 2 and 4). VEGF-C stimulation of PAE cells stably expressing VEGFR-2 led to an even
stronger phosphorylation than the recombinant VEGF-C control. We reasoned that this could indi-
cate the presence of VEGF-A, whose concentrations in seminal plasma have been reported to range
from less than 2 ng/ml to more than 100 ng/ml (Obermair et al., 1999). Indeed, most of the
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Figure 2. KLK3 activation of VEGF-C results in a unique VEGF-C species. KLK3 cleavage results in a mature
VEGF-C species that is N-terminally three amino acids shorter than the ADAMTS3-cleaved VEGF-C. Shown are the
aligned amino acid sequences between the N-terminal propeptide and the receptor binding domain of VEGF-C in
human (h), mouse (m) and rat (r)VEGF-C and hVEGF-D. The arrows mark the sites of proteolytic cleavage of all four
reported VEGF-C-activating enzymes and the two reported cleavage sites in VEGF-D. Residues within the
N-terminal alpha-helix of VEGF-C/D are boxed. Note that the 1st plasmin cleavage site was not verified
experimentally, but deduced from the plasmin cleavage signature and the size of the resulting product. The heat
map under the alignment indicates the areas of highest divergence, deduced from a more comprehensive
alignment of VEGF-C orthologs (see Figure 2—figure supplement 2).
DOI: https://doi.org/10.7554/eLife.44478.005
The following figure supplements are available for figure 2:
Figure supplement 1. Results of the Edman degradation of KLK3-cleaved pro-VEGF-C.
DOI: https://doi.org/10.7554/eLife.44478.006
Figure supplement 2. Interspecies analysis of VEGF-C amino acid sequences relevant for activation.
DOI: https://doi.org/10.7554/eLife.44478.007
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Figure 3. Seminal plasma VEGF-C is cleaved during sperm liquefaction and binds to and activates VEGFR-3. (A) Detection of both pro-VEGF-C and
activated, mature VEGF-C by Western blotting with anti-VEGF-C antibody sc-374628 after pull-down with soluble VEGF receptors or antiserum 882. (B)
Phosphorylation of VEGFR-2 and VEGFR-3 by seminal VEGF-C. Note that the phosphorylation pattern of VEGFR-3 is slightly different from that induced
by 20 ng/ml of the VEGF-C control protein, which corresponds to the plasmin-activated form of VEGF-C. The lower panel shows the same blot
reprobed with Streptactin-HRP for detection of the total levels of VEGFR-3 and VEGFR-2, respectively. (PAS, protein A sepharose; PY, phosphotyrosine)
(C) Fresh seminal fluid contains less processed VEGF-C than seminal fluid liquefied at 37˚C, indicating that pro-VEGF-C is converted into mature
VEGF-C after ejaculation. Effect of protease inhibitors and low temperature on cleavage of VEGF-C (lane 1). While the mature VEGF-C/pro-VEGF-C
ratios of ion sequestered samples (50 mg/ml CHELEX 100 and 5 mM EDTA in lanes 2 and 4, respectively) were not different from the untreated sample
(lane 6), lowering the pH tended to increase the activation of VEGF-C (lane 5), but the difference to untreated sample did not reach statistical
significance. Note that non-liquefied and liquefied samples differ because the semisolid seminogelins largely disappear during liquefaction
(Malm et al., 2000). The semisolid fraction of fresh ejaculate was separately assessed for its VEGF-C content after liquefaction (lane 3). (D)
Quantification of the ratio of mature VEGF-C to pro-VEGF-C in seminal plasma exposed to different conditions. Comparison of the 4˚C sample to
pH ~4.5 (p=0.0066), CHELEX (p=0.045), untreated (p=0.052), and EDTA (p=0.042) [One-way ANOVA, Dunnett’s multiple comparisons test (n = 2), data
are presented as mean ± SEM].
DOI: https://doi.org/10.7554/eLife.44478.008
The following source data and figure supplements are available for figure 3:
Source data 1. Quantification of the ratio of mature VEGF-C to pro-VEGF-C in seminal plasma.
DOI: https://doi.org/10.7554/eLife.44478.012
Figure supplement 1. Comparison of 17 different antibodies for the detection of mature and pro-VEGF-C by Western blotting.
DOI: https://doi.org/10.7554/eLife.44478.009
Figure supplement 2. The VEGFR-2 phosphorylating activity of seminal plasma is blocked by the VEGF-A-capturing VEGFR-2/Fc fusion protein.
DOI: https://doi.org/10.7554/eLife.44478.010
Figure supplement 3. No detection of VEGF-D in seminal plasma.
DOI: https://doi.org/10.7554/eLife.44478.011
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VEGFR-2 phosphorylation was blocked when incubated with soluble VEGFR-2/Fc, but not by incuba-
tion with VEGFR-3/Fc (Figure 3—figure supplement 2). In contrast, VEGF-D was not detected in
seminal plasma (Figure 3—figure supplement 3).
VEGF-C is activated during sperm liquefaction
When fresh ejaculates were immediately mixed with protease inhibitors, placed on ice and analyzed,
less active VEGF-C was detected than in ejaculates that had been liquefied, indicating that pro-
VEGF-C is converted into mature VEGF-C after ejaculation (Figure 3C), concurrently with sperm liq-
uefaction. Lowering the pH with citric acid tended to increase slightly the yield of mature VEGF-C
(Figure 3C, lane 5), but ion chelation with CHELEX 100 or EDTA had no effect (Figure 3C, lanes 2
and 4, respectively).
VEGF-C processing by KLK3 is enhanced by CCBE1
We have shown that CCBE1 enhances the proteolytic activation of VEGF-C by ADAMTS3, but not
by plasmin (Jeltsch et al., 2014). Therefore, we tested whether CCBE1 would accelerate KLK3 acti-
vation of VEGF-C. We found that KLK3-mediated cleavage of VEGF-C was enhanced by CCBE1
when CCBE1 or KLK3 amounts were titrated down so that only little VEGF-C processing occurred
(Figure 4). Substantial amounts of CCBE1 were detected in seminal plasma by Western blotting
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Figure 4. VEGF-C activation by KLK3 is enhanced by CCBE1. (A) Activation of VEGF-C by KLK3 is enhanced by CCBE1. The mature VEGF-C produced
in the presence or absence of CCBE1 is shown in the red and blue boxes, respectively. (B) Quantification of the mature VEGF-C/pro-VEGF-C ratio. Data
are shown as mean ± SD (n = 4). Statistical differences were determined by one-way ANOVA with Tukey post hoc test, ***p<0.001.
DOI: https://doi.org/10.7554/eLife.44478.013
The following source data and figure supplement are available for figure 4:
Source data 1. Quantification of the ratio of mature VEGF-C to pro-VEGF-C to show that activation of VEGF-C by KLK3 is enhanced by CCBE1.
DOI: https://doi.org/10.7554/eLife.44478.015
Figure supplement 1. Seminal plasma contains CCBE1 protein.
DOI: https://doi.org/10.7554/eLife.44478.014
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(Figure 4—figure supplement 1), confirming published proteomics results (Jodar et al., 2016). This
indicates that VEGF-C cleavage could be increased by CCBE1 also in semen.
VEGF-C and VEGF-D activities have different sensitivities to N-terminal
truncations
Activated VEGF-C binds to VEGFR-2 (Joukov et al., 1997), but in our assays with seminal plasma,
VEGFR-2 binding was very weak (Figure 3A, lane 4). To explain this finding, we focused on the
cleavage of the N-terminal helix, because its partial removal in VEGF-D decreases selectively
VEGFR-3 binding while leaving VEGFR-2 binding intact (Leppa¨nen et al., 2011). Since complete pro-
teolytic removal of the N-terminal helix of VEGF-C abolishes all receptor binding and phosphoryla-
tion-stimulating activity (Jeltsch et al., 2014), we first tested if a partial removal of the N-terminal
helix (cutting between Leu-118 and Lys-119, corresponding to the proteolytic cleavage site between
Leu-114 and Lys-115 of VEGF-D) would result in a selective loss of VEGF-C binding to its receptors.
The protease that cleaves between Leu-114 and Lys-115 of VEGF-D (and hypothetically between
the homologous Leu-118 and Lys-119 of VEGF-C) is unknown. Therefore, we generated this form of
VEGF-C by truncating the VEGF-C cDNA, which was then expressed in S2 cells. Interestingly, unlike
the corresponding VEGF-D form, this ‘VEGF-CDMH’ (for ‘D Minor Homology’) bound to VEGFR-3,
but only weakly or not at all to VEGFR-2 (Figure 5A). Because of this unexpected result, we per-
formed the experiment using proteins produced in 293 T cells and found that in conditions where all
other mature forms of VEGF-C interacted with their receptors as predicted, VEGF-CDMH did not
bind to VEGFR-2 or VEGFR-3 (Figure 5B). Since the loss of binding compared to the S2 cell-pro-
duced VEGF-CDMH is not associated with a loss of receptor-interacting amino acid residues, we
attributed the loss of binding to the extra N-terminal four amino acid residues of the mammalian
linker (see also Figure 5—figure supplement 1).
We then used equimolar amounts of truncated VEGF-Cs expressed in transiently transfected
CHO cells (Figure 5—figure supplement 1) to test the bioactivity of different N-terminally truncated
VEGF-Cs in VEGFR-2 and VEGFR-3 phosphorylation assays. The receptor phosphorylation results
mirrored the binding results. The longest mature VEGF-C resulted in the strongest stimulation, and
progressive shortening of the N-terminus resulted in gradually decreased stimulation of the receptor
phosphorylation (Figure 5C). We also tested the activity of purified VEGF-CDMH expressed in S2
cells. In agreement with the binding results, 100 ng/ml VEGF-CDMH did stimulate the phosphoryla-
tion of VEGFR-3 but not or only very weakly of VEGFR-2 (Figure 5D).
A comparison of the sizes of VEGF-C polypeptides produced by S2 cells transfected with N-termi-
nally truncated cDNAs encoding the polypeptide resulting from cleavage by ADAMTS3 and the (lon-
ger) form generated by the 1st plasmin cleavage revealed bands of identical size, indicating
additional proteolytic processing (Figure 5—figure supplement 1). N-terminal sequencing of the
form produced from the longer cDNA revealed that about ⅔ had the KSIDNE. . . N-terminus, and
about ⅓ had AAAHYN... as N-terminus. Hence, the DMH-form of mature VEGF-C can also be pro-
duced by proteolytic processing of a longer mature form of VEGF-C by a yet unknown protease. We
refer to such cleavage on top of an existing activation in the following as secondary activation (irre-
spectively of the receptor activation ability of the resulting protein species).
Cathepsin D activates both VEGF-C and VEGF-D
The presence of a VEGF-C-cleaving protease in seminal fluid prompted us to search for such a prote-
ase also in other body fluids. We enriched the VEGF-C activating component of human saliva by cat-
ion exchange chromatography (Figure 6—figure supplement 1) and subjected the fractions
containing the peak activity to mass spectrometric analysis. Among the highest scoring proteases
(Supplementary file 2), cathepsin D was identified as the most likely candidate due to the cleavage
context of the DMH-form of VEGF-C (Leu-118#Lys-119). Using purified recombinant proteins, we
confirmed that cathepsin D cleaves pro-VEGF-C into active VEGF-C (Figure 6A and Figure 7AB)
and performs a secondary activation of the minor, mature form of VEGF-C (Figure 6A and
Figure 7F). Because the sequence contexts of the cleavage sites of cathepsin D and KLK3 are con-
served between VEGF-C and VEGF-D (see Figure 2), we investigated, if also cathepsin D and KLK3
could activate pro-VEGF-D. Indeed, cathepsin D activated pro-VEGF-D and performed a secondary
activation of the longer, mature form of VEGF-D. The cleavage of mature VEGF-D was rapid and
Jha et al. eLife 2019;8:e44478. DOI: https://doi.org/10.7554/eLife.44478 7 of 30
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Figure 5. Shortening of the VEGF-C N-terminal helix reduces receptor binding and activation. (A) VEGF-CDMH form binds efficiently to VEGFR-3 but
weakly to VEGFR-2 when expressed in S2 cells. (B) Lack of binding of 293T-produced VEGF-CDMH to VEGFR-2 or VEGFR-3. Note that the weak bands
visible in the mock transfected 293T samples are due to endogenous VEGF-A, which binds to VEGFR-2, but not to VEGFR-3 (n = 2). (C) Stimulation of
VEGFR-3 and VEGFR-2 phosphorylation by equimolar amounts of N-terminally truncated VEGF-Cs (corresponding to mature VEGF-C generated by
ADAMTS3, KLK3, and the first plasmin cleavage) expressed in CHO cells (quantification: n = 2 for VEGFR-3; n = 3 for VEGFR-2; data are presented as
mean ± SEM; one-way ANOVA, Tukey’s multiple comparisons test). When compared with control, all three mature VEGF-C forms showed significant
stimulation of both receptors (p-values=0.0094 to<0.0001). (D) Phosphorylation of hVEGFR-3 but not hVEGFR-2 in PAE cells by VEGF-CDMH purified
from S2 cells.
DOI: https://doi.org/10.7554/eLife.44478.016
The following source data and figure supplement are available for figure 5:
Source data 1. Quantification of VEGFR-3 and VEGFR-2 receptor phosphorylation by N-terminally truncated VEGF-Cs.
DOI: https://doi.org/10.7554/eLife.44478.018
Figure supplement 1. Secondary activation of a longer mature VEGF-C form in S2 cells.
DOI: https://doi.org/10.7554/eLife.44478.017
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Figure 6. Cathepsin D activates pro-VEGF-C/D and mature VEGF-C/D, respectively. (A) Cleavage of VEGF-C by coincubation of pro-VEGF-C with
cathepsin D (left panel) and secondary activation of DNDC-VEGF-C (a mature form of VEGF-C translated from a truncated cDNA, right panel). (B)
Quantification of the cleavage of pro-VEGF-C (n = 3) and DNDC-VEGF-C (n = 2) by cathepsin D. (C) Cathepsin-D-mediated conversion of pro-VEGF-D
into mature VEGF-D (left panel), and rapid activation of DNDC-VEGF-D (a mature form of VEGF-D translated from a truncated cDNA, right panel). (D)
Cleavage of pro-VEGF-D by KLK3. Note that, KLK3 cleaves VEGF-D between the VEGF homology domain and the N-terminal propeptide, but also
between the VEGF homology domain and the C-terminal propeptide (for a detailed breakdown of the cleavage products visible in this overlay and the
individual exposures, see Figure 7—figure supplement 2) (n = 2).
DOI: https://doi.org/10.7554/eLife.44478.019
The following source data and figure supplement are available for figure 6:
Source data 1. Quantification of the cleavage of pro-VEGF-C and mature VEGF-C by cathepsin D.
DOI: https://doi.org/10.7554/eLife.44478.021
Figure supplement 1. Enrichment and fractionation of VEGF-C cleaving activity.
DOI: https://doi.org/10.7554/eLife.44478.020
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DOI: https://doi.org/10.7554/eLife.44478.022
The following source data and figure supplements are available for figure 7:
Source data 1. Ba/F3 assay showing the receptor-activating properties of cathepsin D-cleaved VEGF-C and VEGF-D.
DOI: https://doi.org/10.7554/eLife.44478.025
Figure supplement 1. Cathepsin D-cleaved pro-VEGF-D stimulates the phosphorylation of VEGFR-2 in PAE cells.
DOI: https://doi.org/10.7554/eLife.44478.023
Figure supplement 2. KLK3/PSA can proteolytically remove both propeptides from VEGF-D.
DOI: https://doi.org/10.7554/eLife.44478.024
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complete (Figure 6C), whereas the cleavage of both pro-VEGF-C and mature VEGF-C was slower
and incomplete even after 16 hr (Figure 6AB). As expected, the cathepsin D processing of mature
VEGF-D abolished most of its activity in the Ba/F3-VEGFR-3/EpoR assay (Figure 7C) and reduced,
but did not abolish its activity in the Ba/F3-VEGFR-2/EpoR assay (Figure 7D), while processing of
pro-VEGF-D stimulated the phosphorylation of VEGFR-2 (Figure 7—figure supplement 1). KLK3
also activated pro-VEGF-D (Figure 6D and Figure 7E). When VEGF-D was produced from a full-
length cDNA using the baculovirus system, a significant fraction of the protein did not undergo proc-
essing by proprotein convertases. This allowed us to observe two additional KLK3 cleavage sites in
pro-VEGF-D. One of these cleavages has been reported previously (Stacker et al., 1999a); the other
cleavage mimics the C-terminal cleavage catalyzed by proprotein convertases that cleave between
the VHD and the N-terminal propeptide (Figure 6D and Figure 7—figure supplement 2).
In vivo effects of the novel mature VEGF-C forms
To confirm that the two new forms of VEGF-C have also an effect in-vivo, we transduced
mouse skeletal muscle (tibialis anterior) with recombinant adeno-associated viruses serotype 9
encoding the KLK3- or the cathepsin D- (CATD) form of VEGF-C. Both vectors stimulated lymphan-
giogenesis and angiogenesis (Figure 8). As expected on the basis of the binding and receptor phos-
phorylation results, the response to the KLK3-form was stronger compared to the cathepsin D-form.
Both forms appeared to give a stronger response compared to the positive control (the ADAMTS3-
form of VEGF-C), but the higher expression level of the shorter VEGF-C forms likely explains most of
this difference (Figure 8—figure supplement 1).
Discussion
Kallikrein-related peptidase 3 (KLK3) or prostate-specific antigen (PSA) is widely known as a prostate
cancer marker (Lilja et al., 2008), which may also participate in prostate cancer development
(Koistinen and Stenman, 2012). PSA/KLK3 is also the major protease responsible for seminal clot
liquefaction, and thus plays a role in reproduction. In our study, we have found an unexpected link
between these apparently separate functions in the form of Vascular Endothelial Growth Factor-C
(VEGF-C) and VEGF-D.
Requirement for VEGFs during reproduction
The angiogenic effect of VEGF-A is required for example for implantation (Torry et al., 2007) and
corpus luteum formation (Reynolds et al., 2000). VEGF-A levels in human seminal plasma are vari-
able, typically between 10–20 ng/ml (Brown et al., 1995; Obermair et al., 1999), and VEGF-A has
been implicated as a fertility factor that acts on sperm cells (Obermair et al., 1999). Sperm motility
has been reported to increase slightly as a response to VEGF-A (Iyibozkurt et al., 2009), and
overexpression of a testis-specific VEGF-A transgene resulted in infertility (Korpelainen et al.,
1998). VEGF-C is the lymphangiogenic counterpart of VEGF-A, and lymphangiogenesis is required
for ovarian follicle maturation (Rutkowski et al., 2013), corpus luteum formation (Abe et al., 2014;
Nitta et al., 2011) and uterine implantation (Red-Horse, 2008). Furthermore, VEGF-C and VEGF-D
are hormonally regulated in the reproductive system (Nitta et al., 2011).
KLK3/PSA as a VEGF-C activator
The prostate produces KLK3 and contributes active KLK3 to semen. KLK3 is the major protease in
semen and participates in seminal clot liquefaction. KLK3 from human seminal plasma cleaved
VEGF-C between its N-terminal propeptide and the VEGF homology domain. Compared to the
major form of mature VEGF-C, the form produced by KLK3 lacks three amino acid residues from the
N-terminus, but it still activated both VEGFR-2 and VEGFR-3. In vitro, both sperm liquefaction and
VEGF-C exposure to KLK3 resulted in efficient cleavage of VEGF-C. However, in natural insemina-
tion, several factors, such as the vaginal environment or the absent mixing of the early prostatic frac-
tion with the seminal vesicular fluid fraction (Bjo¨rndahl and Kvist, 2003) may interfere with VEGF-C
activation.
Apart from KLK3, seminal plasma also contains many other proteases involved in the proteolytic
liquefaction cascade (Emami and Diamandis, 2013), which might contribute to VEGF-C activation
(and inactivation), including cathepsin D (this study) and plasmin (Jeltsch et al., 2014; Stief, 2007).
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Similar to seminal plasma TGF-b (Robertson et al., 2002), which is also activated during liquefaction
(Emami and Diamandis, 2010), VEGF-C might also contribute to the impregnation-associated
immunomodulation. Several types of immune cells express VEGF-C receptors (Hamrah et al., 2003;
Krebs et al., 2012; Li et al., 2016), and VEGF-C may be responsible for the immune tolerance of
uterine NK cells during pregnancy (Kalkunte et al., 2009). However, since KLK3 exists only in higher
primates (Pavlopoulou et al., 2010), any function of KLK3-mediated VEGF-C activation in seminal
fluid is difficult to address experimentally. On the other hand, mice have many kallikrein-related pep-
tidases that have no human counterparts (Pavlopoulou et al., 2010), and one of these might func-
tionally replace KLK3 as an activator of VEGF-C. Unlike in mice, KLK3 prevents copulatory plug
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Figure 8. The KLK3- and cathepsin D-forms of VEGF-C induce lymphangiogenesis and angiogenesis in vivo. (A) Shown are the immunofluorescent
stainings of the blood and lymphatic vessels in skeletal muscle transduced with recombinant adeno-associated virus subtype 9 (AAV9) encoding the
KLK3- or the cathepsin D (CATD)-form of VEGF-C. Quantification of (B) Lyve-1 positive stained area and (C) CD31 positive stained area in AAV9
transduced tibialis anterior muscle. Data are presented as mean ± SEM, n = 4, one-way ANOVA with Tukey’s post hoc test, ***p<0.001, *p<0.05. Scale
bar, 100 mm. (see also Figure 8—figure supplement 1).
DOI: https://doi.org/10.7554/eLife.44478.027
The following source data and figure supplement are available for figure 8:
Source data 1. In vivo quantification of lymphangiogenesis and angiogenesis induced by KLK3- and cathepsin D-forms of VEGF-C.
DOI: https://doi.org/10.7554/eLife.44478.029
Figure supplement 1. Expression of VEGF-C mRNA in tibialis anterior (TA) muscle.
DOI: https://doi.org/10.7554/eLife.44478.028
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formation in humans, where sperm liquefaction is thought to be a physical requirement for sperm
movement (Mann and Lutwak-Mann, 2012).
KLK3 and tumor (lymph)angiogenesis
VEGF-A inhibition marked a conceptual breakthrough in antiangiogenic cancer treatment
(Ferrara et al., 2005). Although every single VEGF paralog in humans (PlGF, VEGF-B, VEGF-C,
VEGF-D) has been proposed to mediate the tumor escape under anti-VEGF-A treatment (Li et al.,
2014; Lieu et al., 2013), only VEGF-C and VEGF-D activate VEGFR-2 and VEGFR-3 (Achen et al.,
1998; Joukov et al., 1996) and are therefore prime suspects (Kubota, 2012; Li et al., 2014;
Stacker et al., 2001; Wang and Tsai, 2015). VEGF-A is able to activate VEGFR-2 immediately after
secretion, but VEGF-C and VEGF-D need to be proteolytically processed to gain angiogenic
(Joukov et al., 1997; Stacker et al., 1999a) or lymphangiogenic activity (Jeltsch et al., 2014).
The involvement of KLK3/PSA for tumor progression is still debated with studies arguing both in
favor or against a tumor-promoting function of KLK3 (Fortier et al., 1999; Ishii et al., 2004;
LeBeau et al., 2010; Mattsson et al., 2008; Webber et al., 1995). KLK3 expression is largely
restricted to the male prostate (MediSapiens Ltd, 2019; Shaw and Diamandis, 2007), but small
amounts can be found in other tissues, such as Skene’s gland, the female homolog to the prostate
(Zaviacic and Ablin, 2000). In pathological settings, the highest expression levels are found in pros-
tate cancers (MediSapiens Ltd, 2019). We have hypothesized that KLK3 may facilitate early devel-
opment of prostate cancer, but at later stages slow down cancer growth (Koistinen and Stenman,
2012). VEGF-C expression, which overlaps in the prostate with KLK3 expression (Joory et al.,
2006), is similarly controversial, with some studies supporting (Jennbacken et al., 2005; Yang et al.,
2014) and others refuting (Mori et al., 2010) its predictive ability for prostate cancer progression.
Most experimental animal models confirm the role of VEGF-C for metastatic spread
(Brakenhielm et al., 2007; Burton et al., 2008), and potential mechanisms have been identified in
cell culture models (Rinaldo et al., 2007). This study shows that, at least in principle, KLK3 could
contribute to the activation of tumor-derived VEGF-C or VEGF-D and thus to a (lymph)angiogenic
tumor phenotype.
How does CCBE1 accelerate VEGF-C activation?
KLK3 is a serine protease, but like ADAMTS3, its activity towards VEGF-C was increased by CCBE1.
This reinforces the view that CCBE1 interacts with VEGF-C in the trimeric VEGF-C/ADAMTS3/
CCBE1 complex, removing the masking of the cleavage site by the C-terminal domain of VEGF-C
(Joukov et al., 1997). This idea is supported by the ability of the isolated C-terminal domain of
VEGF-C to competitively inhibit CCBE1-accelerated VEGF-C activation by ADAMTS3 (Jeltsch et al.,
2014; Jha et al., 2017). It would also explain why VEGF-C activation by plasmin is not controlled by
CCBE1, as the plasmin cleavage site is located ~10 amino acids residues further away from the
receptor binding epitopes than the ADAMTS3 and KLK3 cleavage sites (see Figure 2).
Cathepsin D activates VEGF-C and VEGF-D with different outcomes
VEGF-CDMH was a designed variant with an N-terminal cleavage resembling that in the minor
(VEGFR-2-specific) form of VEGF-D. After we had established that VEGF-CDMH-like form is produced
by cathepsin D via proteolytic cleavage of a longer VEGF-C polypeptide, we confirmed that also the
VEGFR-2-specific form of VEGF-D (minor, mature form) is indeed produced by cathepsin D cleavage.
However, cathepsin D cleavage affects VEGF-C and VEGF-D activities differently. While VEGF-D
loses practically all binding affinity towards VEGFR-3, VEGF-C seems to lose preferentially its affinity
towards VEGFR-2.
The minor mature form of VEGF-D was identified in the supernatant of VEGF-D-producing 293
cells (Stacker et al., 1999a), where VEGF-CDMH was not detected (Joukov et al., 1997), presumably
because cathepsin D-cleavage of VEGF-C is inefficient. Alternatively, the ADAMTS3-cleavage of
VEGF-C in 293 cells may have preemptively removed the recognition epitope required for cathepsin
D cleavage.
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Secondary cleavage results in additional VEGF-C and VEGF-D species
Our data show that the longest forms of mature VEGF-C and VEGF-D can undergo secondary activa-
tion (i.e. N-terminally cleaved on top of a prior, activating cleavage). This introduces an additional
layer of complexity into the regulation of VEGF-C and VEGF-D signaling since the cathepsin D-cleav-
age abolishes the VEGFR-3 binding of VEGF-D and reduces the VEGFR-2 binding of VEGF-C.
Cathepsin D is ubiquitously expressed, and although it is involved predominantly in lysosomal
protein degradation (Benes et al., 2008), it can be secreted and soluble cathepsin D is found in
saliva (our present findings) and in seminal plasma (Jodar et al., 2016). Secondary activation by
cathepsin D may explain why we saw only weak VEGF-C-VEGFR-2 interaction when analyzing semi-
nal plasma. It should be noted that cathepsin D has also been implicated in cancer metastasis
(Benes et al., 2008; Spyratos et al., 1989), where VEGF-C can also play a role (Karpanen et al.,
2001; Mandriota et al., 2001; Skobe et al., 2001). However, the cathepsin D-mediated secondary
activation of the major, mature form of VEGF-D was very rapid, when compared to the very slow
activation of VEGF-C (compare Figure 6A and C). Therefore, VEGF-D activation appears to be a
more relevant function of cathepsin D than VEGF-C activation. The cathepsin D-processed minor
form of mature VEGF-D showed a lower potency to activate VEGFR-2 than the major form of mature
VEGF-D, likely reflecting the corresponding KD values (Leppa¨nen et al., 2011). Despite this, as a net
effect, cathepsin D cleavage of VEGF-D may result in increased angiogenic activity.
The role of the N-terminal helix
In VEGF-A, the N-terminal helix in the VEGF homology domain appears essential for the receptor
dimerization and activity (Siemeister et al., 1998), whereas the platelet derived growth factor does
not need an N-terminal helix for receptor binding (Muller et al., 1997; Shim et al., 2010). The
Leu119#Lys120 (cathepsin D) cleavage of VEGF-C happens within the N-terminal helix, which con-
tains binding epitopes for VEGFR-2 (Leppa¨nen et al., 2010). The N-terminal helix also interacts with
VEGFR-3. However, mutating the contacting amino acid residues Asp123 and Gln130 only amelio-
rates binding of VEGF-C to VEGFR-3 (Leppa¨nen et al., 2013). The present receptor phosphorylation
data strongly suggest that shortening of the helix leads to decreased activation of both VEGFR-2
and VEGFR-3, whereas a complete or near-complete removal of the N-terminal alpha helix- for
example by extended plasmin exposure - abolishes all receptor binding. Inline with this, both the
KLK3- and the cathepsin D-forms of VEGF-C induced lymphangiogenesis and angiogenesis in skele-
tal muscle. The N-terminal helix of VEGF-C is largely conserved among vertebrates, but the C-termi-
nal end of the N-terminal propeptide and linker preceding the VEGF homology domain represent
the most diverse sequences among VEGF-Cs in different species. These differences are especially
noticeable between fish and the rest of the vertebrate clade (Figure 2—figure supplement 2), indi-
cating potential differences in the VEGF-C activation.
Separate activating proteases for each specific task?
Although ADAMTS3 appears to be responsible only for developmental lymphangiogenesis, our
study indicates that other proteases may activate VEGF-C for specific niche functions, for example
KLK3 in the reproductive system. The possible involvement of cathepsin D and KLK3 in tumor metas-
tasis could be addressed in the appropriate gene-targeted mouse models. The possible other niche
functions of VEGF-C, for example in the central nervous system (Mackenzie and Ruhrberg, 2012),
in osmoregulation (Machnik et al., 2009) or in the immune system (Loffredo et al., 2014), may also
be controlled by differentially regulated proteases.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Cell line
(M. musculus)
Ba/F3-hVEGFR-3/
EpoR
Achen et al., 2000 Murine pro-B cells
expressing a chimeric
VEGFR-3, from reference
lab
Cell line
(M. musculus)
Ba/F3-mVEGFR-2/
EpoR
Stacker et al., 1999b Murine pro-B cells
expressing a chimeric
VEGFR-2, from
reference lab
Cell line
(Sus scrofa domesticus)
PAE-VEGFR-3-
StrepIII
Leppa¨nen et al., 2013 Porcine aortic endothelial
cells expressing strep-tagged
VEGFR-3, from reference lab
Cell line
(Sus scrofa domesticus)
PAE-VEGFR-2
-StrepIII
Anisimov et al., 2013 Porcine aortic endothelial
cells expressing strep-
tagged VEGFR-2, from
reference lab
Cell line
(Sus scrofa
domesticus)
PAE-VEGFR-3 Pajusola et al., 1994 Porcine aortic endothelial
cells expressing untagged
VEGFR-3, from reference
lab
Cell line
(Sus scrofa
domesticus)
PAE-VEGFR-2 Waltenberger et al., 1994 Porcine aortic endothelial
cells expressing untagged
VEGFR-2, from reference
lab
Cell line
(Homo sapiens)
293T ATCC RRID:CVCL_0063 Human embryonic kidney
cells, from vendor
Cell line
(Cricetulus griseus)
CHO DG44 Invitrogen Chinese hamster ovary
cells, from vendor
Cell line
(Drosophila
melanogaster)
Schneider S2 cells Invitrogen Insect cells for protein
production (Drosophila
expression system), from
vendor
Cell line
(Spodoptera
frugiperda)
Sf9 Invitrogen Insect cells for protein
production (FactBac system),
from vendor
Transfected
construct
pMT-Ex-VEGF-C-DMH This paper. 1271* Production of the cathepsin
D-cleaved form of VEGF-C
in S2 cells
Transfected
construct
pMT-hygro-BiPSP-
hVEGF-C-FL
This paper. 751* Production of untagged
pro-VEGF-C in S2 cells
Transfected
construct
pSecTagI-IgKSP-
DNDC-hVEGF-C-H6
This paper. 2242* Production of the
plasmin1-cleaved form
of VEGF-C (primary plasmin
cleavage, between VEGF-C
aa 102 and 103)
Transfected
construct
pSecTagI-IgKSP-
DNDC-VEGF-C-
ADAMTS3-H6
This paper. 2313* Production of the ADAMTS3
-cleaved form of VEGF-C
(cleavage between aa
residues 111 and 112)
Transfected
construct
pSecTagI-IgKSP-
DNDC-VEGF-C-
KLK3-H6
This paper. 2312* Production of the
KLK3-cleaved form of
VEGF-C (cleavage between
aa residues 114 and 115)
Transfected
construct
pSecTagI-IgKSP-
DNDC-VEGF-C-
CATD-H6
This paper. 2315* Production of the
cathepsin D-cleaved
form of VEGF-C (cleavage
between aa residues 119
and 120)
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Transfected
construct
pSecTagI-IgKSP-
DNDC-VEGF-C-
plasmin2-H6
This paper. 2314* Production of the
plasmin2-cleaved form
of VEGF-C (secondary
plasmin cleavage, between
VEGF-C aa 127 and 128)
Transfected
construct
pSecTagI-IgKSP-
DNDC-VEGF-
C(C156S)-H6
This paper. 2318* Production of the mature
form of the VEGF-C-C156S
mutant (primary plasmin
cleavage, between VEGF-C
aa 102 and 103)
Transfected
construct
pMX-hCCBE1-StrIII Jeltsch et al., 2014 1494* Production of full-length
CCBE1
Transfected
construct
psubCAG-WPRE-
IgKSP-DNDC-hVEGF-
C-KLK3
This paper. 2380* Generation of recombinant
adeno-associated virus
Transfected
construct
psubCAG-WPRE-
IgKSP-DNDC-hVEGF-
C-CATD
This paper. 2351* Generation of recombinant
adeno-associated virus
Transfected
construct
psubCMV-WPRE-IgKSP
-DNDC-hVEGF-C-
ADAMTS3
Anisimov et al., 2009 Generation of recombinant
adeno-associated virus
(positive control)
Transfected
construct
psubCMV-WPRE Paterna et al., 2000 Generation of recombinant
adeno-associated virus
(negative control)
Transformed
construct
pFB1-melSP-
hVEGF-D-FL-H6
This paper and
Achen et al., 1998
229* Generation of recombinant
baculovirus (FastBac system)
Transformed
construct
pFB1-melSP-
DNDC-hVEGF-D-H6
This paper and
Achen et al., 1998
118* Generation of recombinant
baculovirus (FastBac system)
Biological
sample (H. sapiens)
human saliva collected from
authors of this paper
Biological
sample (H. sapiens)
human seminal plasma collected from
authors of this paper
Antibody anti-VEGF-C antiserum,
rabbit polyclonal
Baluk et al., 2005 AS no. 6 WB (1:2000)
Antibody anti-VEGF-C antiserum,
rabbit polyclonal
Joukov et al., 1997 AS 882 WB (1:1000)
IP (1:500-1:1000)
Antibody anti-VEGF-C antiserum,
rabbit polyclonal
Joukov et al., 1997 AS 905 WB (1:500)
Antibody anti-VEGF-C antiserum,
rabbit polyclonal
This paper. AS 885 WB (1:250)
Antibody anti-VEGF-C antiserum,
rabbit polyclonal
This paper. AS 890 WB (1:250)
Antibody anti-VEGF-C antiserum,
rabbit polyclonal
This paper. AS no. 3/4 WB (1:1000)
Antibody anti-VEGF-C antibody,
rabbit polyclonal
Abcam RRID:AB_2241408 WB (1:1000)
Antibody anti-VEGF-C antibody,
rabbit polyclonal
Abcam ab135506 WB (1:1000)
Antibody anti-VEGF-C antibody,
rabbit polyclonal
Novus/
Biotechne
NB110-61022 WB (1:1000)
Antibody anti-VEGF-C antibody,
rabbit polyclonal
Cell Signaling
Technology
RRID:AB_2213314 WB (1:1000)
Antibody anti-VEGF-C antibody,
rabbit polyclonal
Invitrogen/ThermoFisher RRID:AB_2547246 WB (1:500)
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Antibody anti-VEGF-C antibody,
rabbit polyclonal
Sigma-Aldrich/Merck SAB1303101 WB (1:500)
Antibody anti-VEGF-C antibody,
rabbit polyclonal
Sigma-Aldrich
/Merck
SAB1303607 WB (1:500)
Antibody anti-VEGF-C antibody,
goat polyclonal
R and D Systems
/Biotechne
RRID:AB_2241406 WB (1:1000)
Antibody anti-VEGF-C antibody,
mouse monoclonal
Santa Cruz
Biotechnology
RRID:AB_11012156 WB (1:500)
Antibody anti-VEGF-C antibody,
mouse monoclonal
Santa Cruz
Biotechnology
RRID:AB_1131232 WB (1:500)
Antibody anti-VEGF-C antibody,
mouse monoclonal
R and D Systems
/Biotechne
RRID:AB_2213313 WB (1:500)
Antibody anti-VEGF-C antibody,
mouse monoclonal
Invitrogen
/ThermoFisher
RRID:AB_2725653 WB (1:200)
Antibody anti-VEGF-C antibody,
mouse monoclonal
Sigma-Aldrich
/Merck
SAB1306762 WB (1:100)
Antibody anti-KLK3 antibody,
mouse monoclonal
Stenman et al., 1999 5C7 neutralization at
2-fold molar excess
Antibody anti-VEGF-D, goat
polyclonal
R and D Systems
/Biotechne
RRID:AB_355293 WB (1:1000)
Antibody anti-phosphotyrosine
antibody 4G10,
mouse monoclonal
Millipore/
Merck
RRID:AB_309678 WB (1:5000)
Antibody anti-VEGFR-2, goat
polyclonal
R and D Systems
/Biotechne
RRID:AB_355320 WB (1:1500)
Antibody anti-VEGFR-3, mouse
monoclonal
Dumont et al., 1998 9D9F9 WB (1:1000)
Antibody anti-CCBE1, rabbit
polyclonal
Atlas Antibodies
/Sigma-Aldrich/
Merck
RRID:AB_10794515 WB (1:1000)
Antibody PentaHis Antibody,
mouse monoclonal
Qiagen RRID:AB_2619735 WB (1:1500)
Antibody anti-mouse Lyve-1,
rabbit polyclonal
Karkkainen et al., 2004 IF (1:1000)
Antibody anti-mouse CD31,
rat monoclonal
BD Biosciences RRID:AB_393571 IF (1:500)
Antibody HRP-conjugated
Strep-Tactin
IBA 2-1502-001 1:100000
Antibody Donkey anti-goat
IgG
Jackson Immuno
Research
RRID:AB_2340390 1:2500
Antibody Goat anti-mouse
IgG
Jackson Immuno
Research
RRID:AB_10015289 1:2500
Antibody Goat anti-rabbit
IgG
Jackson Immuno
Research
RRID:AB_2313567 1:2500
Antibody Alexa 488 donkey
anti-rat
Molecular Probes/
Thermo Fisher
RRID:AB_2535794 1:500
Antibody Alexa 594 donkey
anti-rabbit
Molecular Probes/
Thermo Fisher
RRID:AB_141637 1:500
Recombinant
protein
KLK3 Wu et al., 2004;
Zhang et al., 1995
isoform B
Recombinant
protein
Cathepsin D (CATD) R and D Systems/
Biotechne
1014-AS
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Recombinant
protein
pro-VEGF-C This paper. 751* untagged pro-VEGF-C
Recombinant
protein
DNDC-VEGF-C or
mature VEGF-C
Ka¨rpa¨nen et al., 2006 792* C-terminally histagged
mature human VEGF-C
(minor form)
Recombinant
protein
VEGF-CDMH This paper. 2454* DMH form of human
VEGF-C expressed in
S2 cells
Recombinant
protein
pro-VEGF-D Achen et al., 1998 229* C-terminally histagged
human pro-VEGF-D
Recombinant
protein
DNDC-VEGF-D or
mature VEGF-D
Achen et al., 1998 118* C-terminally histagged
mature human VEGF-D
(major form)
Recombinant
protein
CCBE1-StrepIII Jeltsch et al., 2014 1494* StrepIII-tagged human
CCBE1 protein
Recombinant
protein
VEGFR-3/Fc Jeltsch et al., 2006 810* human VEGFR-3
extracellular domains
1–7 fused to IgG1Fc
Recombinant
protein
VEGFR-2/Fc Leppa¨nen et al., 2013;
Leppa¨nen et al., 2010
321* human VEGFR-2
extracellular domains
1–3 fused to IgG1Fc
Commercial
assay or kit
Human VEGF-C
Quantikine ELISA
Kit
R and D Systems/
Biotechne
DVEC00
Chemical
compound,
drug
streptactin resin/
sepharose
IBA 2-1201-010
Chemical
compound,
drug
Protein A-Sepharose-4B
beads CL-4B (PAS)
GE Healthcare 17-0780-01
Chemical
compound,
drug
Chelex 100 Bio-Rad 1421253
Chemical
compound,
drug
cOmplete Roche 11697498001
Other VECTASHIELD
mounting medium
with DAPI
Vector Laboratories RRID:AB_2336790 nucleic label
*The asterisk denotes internal lab numbering of the corresponding DNA prep.
Protein production and purification
KLK3 (isoform B) was purified by immunoaffinity chromatography from pooled seminal plasma
(Wu et al., 2004). The separation of the different isoforms by anion-exchange chromatography was
performed as described (Zhang et al., 1995). For the production of untagged pro-VEGF-C, full-
length human VEGF-C cDNA was cloned into the Drosophila expression vector pMT-BiP (Invitrogen/
Thermo Fisher Scientific, Waltham, MA). The protein was expressed in stably transfected S2 cells in
Insect-Xpress medium (Lonza, Basel, Switzerland) supplemented with 250 mg/ml hygromycin at 26˚C.
The cells were induced with 1 mM CuSO4 and the conditioned medium was harvested 4 days post-
induction. VEGF-C was purified from the conditioned medium by Heparin affinity chromatography
(HiTrap Heparin HP, GE Healthcare, Chicago, IL) at pH 6.7, followed by cation exchange chromatog-
raphy over a MonoS or HiTrap SP HP column (GE Healthcare) at the same pH and gel filtration on a
Superdex 200 Increase (GE Healthcare) column in PBS. C-terminally his-tagged pro-VEGF-D was pro-
duced with the baculovirus system as described (Achen et al., 1998). Purification was performed by
affinity chromatography over Excel sepharose (GE Healthcare), followed by gel filtration as
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described for pro-VEGF-C. C-terminally his-tagged mature VEGF-D was produced from a truncated
cDNA analogous to pro-VEGF-D. CCBE1 protein was produced and purified as described
(Jeltsch et al., 2014). Similarly, human VEGFR-3/Fc (containing extracellular domains 1–7) and
VEGFR-2/Fc (containing extracellular domains 1–3) were purified as described (Jeltsch et al., 2006;
Leppa¨nen et al., 2013; Leppa¨nen et al., 2010).
Recombinant Adeno-Associated viral vector production
Recombinant Adeno-Associated Viruses (AAVs) were produced as previously described
(Jeltsch et al., 2014).
Cell lines
Stably transfected cell lines were obtained directly from the generating laboratories (indicated by
the reference in the key resource table) and other cell lines were obtained from the indicated ven-
dors, who authenticate and monitor for mycoplasma status of these products according to applica-
ble regulations.
Antibodies
All anti-VEGF-C antibodies are listed in the Supplementary file 1. We used further the following
antibodies: anti-phosphotyrosine antibody 4G10 (Merck/Millipore), anti-VEGFR-3 antibody sc-321
(Santa Cruz Biotechnology, Dallas, TX), anti-VEGFR-2 (AF357, R and D Systems, Minneapolis, MN),
anti-VEGF-D (AF286, R and D Systems), anti-CCBE1 (HPA041374, Atlas Antibodies/Sigma-Aldrich/
Merck), and Penta-His antibody (#34660, Qiagen, Hilden, Germany).
For the immunofluorescence, the primary antibodies anti-CD31 (BD Biosciences) and anti-Lyve-1
(Karkkainen et al., 2004) were detected using the appropriate Alexa Fluor 488 and 594 secondary
antibody conjugates (Molecular Probes/Invitrogen). Antiserum (AS) no. 3/4, AS 885 and AS 890 were
generated like AS no. 6 (Baluk et al., 2005), except that mature VEGF-C (Ka¨rpa¨nen et al., 2006)
was used as the antigen instead of pro-VEGF-C for AS no. 3/4, and peptide antigens (see
Supplementary file 1 for details) for AS 885 and AS 890.
Activation of pro-VEGF-C and pro-VEGF-D by KLK3
0.94 mg of purified KLK3 was incubated with 1.7 mg of recombinant growth factor in TBS pH 7.7 at
37˚C for 24 hr, if not differently indicated. For blocking, the monoclonal antibody against KLK3, 5C7
(Stenman et al., 1999) was used in 2-fold molar excess and the cleavage was analyzed by SDS-
PAGE/Western using antiserum 6 and 3/4 (VEGF-C) and AF286 (VEGF-D, R and D Systems). For
CCBE1-enhanced cleavage experiments, 10 ml CCBE1-StrepIII (equal to the amount of CCBE1 puri-
fied from 12.5 ml of conditioned 293T medium) were included in the reaction.
Activation of VEGF-C and VEGF-D by cathepsin D
80 mg of pro-VEGF-C/pro-VEGF-D in 240 ml PBS or DNDC-VEGF-C/DNDC-VEGF-D in 60 ml PBS were
incubated with the same volume of human, recombinant cathepsin D, which had been activated and
diluted according to the instructions of the manufacturer (1014-AS, R and D Systems). Incubation
was performed at 37˚C, and aliquots were taken at 15 min, 1 hr, 4 hr and 16 hr and frozen at  80˚C
until analysis. Samples were resolved by reducing SDS-PAGE and proteins were visualized by Coo-
massie Blue staining. The activation of pro-VEGF-D and DNDC-VEGF-D was visualized by Western
blotting.
Transfections, Metabolic Labeling
293T and CHO cell transfections and procedures were performed as described (Jeltsch et al.,
2014).
Edman degradation
For the N-terminal sequence analysis, the digestion mixture of purified KLK3 and recombinant pro-
VEGF-C or purified protein was resolved by SDS-PAGE and blotted to a PVDF membrane using
1xCAPS buffer/10% methanol. The membrane was Coomassie-stained and the band at 20 kDa was
excised after destaining with 50% methanol. Edman degradation was performed using a Procise 494
Jha et al. eLife 2019;8:e44478. DOI: https://doi.org/10.7554/eLife.44478 19 of 30
Research article Cancer Biology
HT sequencer (Applied Biosystems/Thermo Fisher Scientific) and data analyzed with the Sequence
Pro software. Multiple N-termini were disambiguated by a fuzzpro search (Rice et al., 2000) of the
major peaks against the VEGF-C and KLK3 sequences and eliminating results incompatible with the
molecular weight observed on the gel.
Ba/F3-VEGFR/EpoR Assays
The Ba/F3-hVEGFR-3/EpoR (Achen et al., 2000) and Ba/F3-mVEGFR-2/EpoR (Stacker et al., 1999b)
bioassays were performed with recombinant proteins as described (Ma¨kinen et al., 2001).
VEGF-C activation in seminal plasma
Fresh ejaculates, showing normal sperm parameters (Cooper et al., 2010), were collected from
healthy volunteers among the authors (three different individuals) in full agreement with local regula-
tions and institutional oversight. For analysis by SDS-PAGE/Western blotting, seminal plasma was
separated from the cellular fraction and debris after approximately 30 min of liquefaction at RT by
centrifuging twice for 10 min (at 1000 g and 10000 g). Seminal plasma was stored at  80˚C until fur-
ther analyses. Prior to analysis, thawed seminal plasma samples were sonicated and centrifuged
again for 10 min at 16000 g at 4˚C. The upper white layer was discarded and the clear fraction was
collected for analyses.
To test the effects of divalent cation concentration and pH on the cleavage of VEGF-C in seminal
plasma, 50 mg of Chelex 100 Resin (Bio-Rad, Hercules, CA), 10 ml 0.5M EDTA, or 25 ml 0.1M citric
acid were added during the initial liquefaction to each ml of seminal fluid, and samples were incu-
bated for 24 hr at 37˚C before continuing with the centrifugation steps.
To slow the proteolytic liquefaction cascade, fresh ejaculates were immediately transferred to ice
and a protease inhibitor cocktail (cOmplete, Roche) pre-dissolved in PBS was added at twice the rec-
ommended final concentration. Two centrifugation steps of 10000 g were performed at 4˚C to sepa-
rate the cellular and gel fraction from the liquid phase and samples were stored at  80˚C until
further analysis. Before the gel fraction was loaded, it was incubated at 37˚C until liquefaction.
Immunoprecipitation, SDS-PAGE, Western blotting and protein analysis
For precipitation with antibodies or soluble receptors, the seminal plasma samples (processed as
described above) were diluted 1 + 1 with PBS and incubated with 30 ml protein A-Sepharose-4B
beads and the respective antibody or soluble receptor overnight at 4˚C. The beads were washed
three times with PBS/0.05% Tween-20 and the bound proteins were eluted by adding 30 ml of 2X
Laemmli standard buffer (LSB) followed by heating at 95˚C for 10 min. For direct loading of proteins
(digestion analysis of VEGF-C and VEGF-D, CCBE1 from seminal plasma), 2x or 5x LSB was added to
the samples prior to boiling. For Western blotting, proteins were resolved on SDS-PAGE, transferred
to PVDF membranes, blocked with 5% BSA in TBS-T for 1 hr and probed overnight with the relevant
primary antibodies. The membranes were incubated with the appropriate HRP-conjugated second-
ary antibodies (Jackson Immuno Research, Cambridgeshire, UK, anti-rabbit IgG (111-035-003), anti-
mouse IgG (115-035-003) or anti-goat IgG (705-035-003), 1:2500 in 5% skimmed milk in TBS-T) for 1
hr at RT and bands were visualized with ECL plus Western Blotting Substrate (Pierce/Thermo Fisher
Scientific, Waltham, MA) or SuperSignal West Femto Maximum Sensitivity Substrate (Pierce/Thermo
Fisher Scientific) using the LI-COR Odyssey Fc or cDigit Imaging System (Li_COR, Lincoln, NE).
Direct visualization of proteins in the PAGE gels was performed by Coomassie Blue or silver staining.
ELISA
The level of VEGF-C in seminal plasma (processed as described above) was estimated using the
Human VEGF-C Quantikine ELISA Kit (DVEC00, R and D Systems) following the manufacturer’s
instructions.
Stimulation of VEGFR-3 and VEGFR-2 phosphorylation
Near confluence, PAE cells expressing strep-tagged VEGFR-3 (Leppa¨nen et al., 2013) or VEGFR-2
(Anisimov et al., 2013) were washed with PBS and starved for 4–5 hr in DMEM. PAE cells expressing
untagged VEGFR-3 or VEGFR-2 starved for 16 hr in DMEM/0.1% BSA were used to analyze N-termi-
nally truncated VEGF-Cs. The cells were stimulated for 10 min with sonicated centrifugation-cleared
Jha et al. eLife 2019;8:e44478. DOI: https://doi.org/10.7554/eLife.44478 20 of 30
Research article Cancer Biology
seminal plasma diluted 1 + 1 with PBS (as described above), 20 ng/ml DNDC-VEGF-C
(Ka¨rpa¨nen et al., 2006) or equimolar amounts of N-terminally truncated VEGF-Cs (adjusted after
quantification of VEGF-C levels in conditioned supernatant after transient transfection of CHO cells)
to detect phosphorylation of VEGFR-3 and VEGFR-2. Then, the cells were washed twice with ice-
cold PBS, lysed with modified RIPA buffer (50 mM Tris-HCl pH 8, 0.5% NP-40, 0.5% Triton X-100,
EDTA-free protease inhibitor cocktail (cOmplete, Roche, Pleasanton, CA), 0.1 mM PMSF, 1 mM
Na3VO4, and 1 mM NaF). VEGFR-3 and VEGFR-2 were precipitated from the cell lysate using Strep-
Tactin Sepharose (IBA, Go¨ttingen, Germany) for strep-tagged VEGFR-2/–3 or immunoprecipitated
using protein A Sepharose (PAS) and anti-VEGFR-3 (clone 9D9F9, Dumont et al., 1998) or anti-
VEGFR-2 (AF357, R and D Systems), washed three times with PBS/0.05% Tween-20/1 mM Na3VO4
and eluted with 2x Laemmli buffer and analyzed by SDS-PAGE/Western blot using the phospho-tyro-
sine-specific antibody 4G10 (Merck/Millipore, Darmstadt, Germany, 1:5000). Membranes were
stripped using Re-Blot plus strong solution (Merck/Millipore) and re-probed with HRP-conjugated
Strep-Tactin (IBA, 1:100000), anti-VEGFR-3 (9D9F9) or anti-VEGFR-2 (AF357) to verify equal loading.
Fractionation of human saliva and VEGF-C cleavage activity assay
7 ml of filter-sterilized saliva collected from volunteers among the authors in agreement with local
regulations were diluted 1 + 2 with running buffer (20 mM sodium acetate, pH 4.67) and loaded
onto a MonoS column (GE Healthcare). After washing with running buffer, elution was performed
with a linear 0–1M NaCl gradient and 1 ml fractions were collected. 20 ml of each fraction were
diluted 1 + 4 with running buffer and 1.3 mg of pro-VEGF-C was added. After 36 hr incubation at 37˚
C, a Ba/F3-VEGFR-3/EpoR assay was performed with the samples.
Interspecies analysis of VEGF-C sequences
Amino acid sequences of 40 VEGF-C orthologs representing all major vertebrate groups (fish,
amphibians, reptiles, birds, mammals) were retrieved via a blastp search against human VEGF-C
(UniProtKB P49767). To analyze clade-specific differences in the sequence context of the VEGF-C-
activating cleavage, the sequences were truncated to include only sequences corresponding to
human VEGF-C amino acids 55 to 228 (i.e. from the center of the N-terminal propeptide to the end
of the VEGF homology domain). Alignment was performed with m_coffee (Wallace et al., 2006) and
the sequences attached to the tip nodes of a phylogenetic species tree generated by opentree
(Hinchliff et al., 2015). The results were rendered with the ETE toolkit (Huerta-Cepas et al., 2016).
A Python script of the complete workflow is available from GitHub (Jeltsch, 2018; copy archived at
https://github.com/elifesciences-publications/VEGFC).
Mass spectrometric analysis
Six bands, with identical replicates, were cut from a Coomassie-stained SDS-PAGE gel. Samples
were in-gel digested according to the standard protocols and analyzed by LC-ESI-MS/MS using the
LTQ Orbitrap Velos Pro mass spectrometer (Thermo Fisher Scientific). The data files were searched
for protein identification using Proteome Discoverer 1.4 software (Thermo Fisher Scientific) con-
nected to a server running Mascot 2.4.1 (Matrix Science, Boston, MA). Data were searched against
the SwissProt database (release 2014_01). The following search parameters were used: type of
search - MS/MS Ion Search, taxonomy - human, enzyme - trypsin, fixed modifications - carbamido-
methyl (C), variable modifications - oxidation (M), mass values - monoisotopic, peptide mass toler-
ance - ± 5 ppm, fragment mass tolerance - ± 0.5 Da, max missed cleavages - 1, instrument type -
ESI-TRAP. Only proteins assigned at least with two unique peptides were accepted.
Cloning
The pMX-hCCBE1-StrIII construct has been described before (Jeltsch et al., 2014). The S2 cell-
expression vector pMT-Ex-VEGF-C-DMH was generated by deleting the 51 nucleotides coding for
amino acids 103 to 119 of VEGF-C from pMT-Ex-DNDC-VEGF-C-H6, a modified pMT/BiP/V5-His C
vector (Invitrogen/Thermo Fisher Scientific), expressing mature VEGF-C (Ka¨rpa¨nen et al., 2006).
pMT-hygro-BiPSP-hVEGF-C-FL (for the production of untagged pro-VEGF-C) was generated by
PCR-amplification of sequences corresponding to amino acids 32–419 of VEGF-C and cloning of the
product into BglII-opened pMT-BiPV5HisC-hygro, another derivative of pMT/BiP/V5-His C, in which
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the 260 bp SapI-AccI fragment had been replaced by the SapI-AccI hygromycin expression cassette
from pCoHygro (Invitrogen/Thermo Fisher Scientific).
pSecTagI-IgKSP-DNDC-hVEGF-C-H6 (the mammalian vector expressing mature VEGF-C corre-
sponding to VEGF-C activated by plasmin cleavage between VEGF-C amino acids 102 and 103) was
constructed by inserting the BamHI/BclI-cut VEGF-C PCR amplification product of primers 5’-GA
TGCTCGAGGATCCGACAGAAGAGACTATAAAATTTGC-3’ and 5’-GCATGATCACAGTTTAGACA
TGC-3’ into the BamHI-opened pMosaic vector (Jeltsch et al., 2006). The cDNAs coding for N-ter-
minally truncated VEGF-C (corresponding to mature VEGF-C forms as activated by KLK3 cleavage,
ADAMTS3 cleavage, and plasmin cleavage between amino acid residues 127 and 128) were PCR
amplified from pSecTagI-IgKSP-DNDC-hVEGF-C-H6 using specific forward primers (5’-TCCG GA
TCCGGATCCAAATACAGAGATCTTGAAAAGTATTGATAATGAGTGG-3’; 5’-TC CGGATCCGGA
TCCAGCACATTATAATACAGAGATCTTGAAAAGTATTG-3’; and 5’-TCCGGATCCGGATCCAAA-
GACTCAATGCATGCCACG-3’) and the same reverse primer (5’-ACCTACTCAGACAATGCGATGC-
3’), and subcloned into pSecTagI-IgKSP-DNDC-hVEGF-C-H6 as BamHI-EcoRI fragments. The DMH/
CatD form and C156S mutant of VEGF-C were subcloned in the same fashion from pMT-Ex-VEGF-C-
DMH and pREP7-VEGF-C-C156S (Joukov et al., 1998) into the same vector (using forward primers
5’-CGGATCCAAAAAGTATTGATAATGAGTGGAGA-3’ and 5’-GCGGATCCGACAGAAGAGACTA
TAAAA-3’ and reverse primer 5’-GGAATTCAATGATGATGATGGTGATGCAGTTTAGACATGC-3’).
The shuttle vectors to produce pro-VEGF-D (pFB1-melSP-hVEGF-D-FL-H6) and a mature form of
VEGF-D (pFB1-melSP-DNDC-hVEGF-D-H6) with the baculovirus system were generated by restric-
tion-cloning the BamHI/HindIII-fragments of the PCR products of primers 5’-TGCGGATCCCTCCAG
TAATGAACATGGACCAGTGAAGCGATC-3’ and 5’-GACAAGCTTAATGATGATGATGGTGA
TGAGGATTCTTTCGGCTGTGGGGC-3’ (for pro-VEGF-D) and 5’-TGCGGATCCGTCAGCATCCCA
TCGGTCCACTAGGTTTG-3’ and 5’-GACAAGCTTAATGATGATGATGGTGATGGGGGGCTG
TTGGCAAGCACTTAC-3’ (for mature VEGF-D) into a modified pFASTBAC1 vector (Gerhardt et al.,
2003).
Cloning of AAV9 constructs
The sequence coding for the Immunoglobulin Kappa signal peptide was amplified using forward
primer 5’-CTAAAAGCTGCGGAATTGTACCCGCGGCCGCTAGCGCCACCATGGAGACAGAC-3’ and
reverse primer 5’-GTCACCAGTGGAACCTGG-3’ and the VEGF-C CDS was amplified using forward
primer 5’-CTGCTCTGGGTTCCAGGTTCCACTGGTGACAAAAGTATTGATAATGAGTGGAGAAA-
GAC-3’ and reverse primer 5’-AAATTTTGTAATCCAGAGGTTGATTATCGACGCGTTCAACGTCTAA
TAATGGAATGAACT-3’. Both fragments were assembled into a MluI- and NheI-opened and CIPped
psubCAG-WPRE vector (Weltner et al., 2012) resulting in psubCAG-WPRE-IgKSP-DNDC-hVEGF-C-
CATD. psubCAG-WPRE-IgKSP-DNDC-hVEGF-C-KLK3 was assembled as above, but the reverse
primer for the Immunoglobulin Kappa signal peptide CDS amplification was replaced by 5’-TTA
TCAATACTTTTCAAGATCTCTGTATTGTCACCAGTGGAACCTGG-3’ and the forward primer for
VEGF-C CDS amplification by 5’-CAATACAGAGATCTTGAAAAGTATTGATAATG-3’.
In vivo experiments
AAV9s (dose of 4  1010 in 40 ml) encoding negative control, positive control (ADAMTS3-cleaved
form of VEGF-C), KLK3-cleaved form of VEGF-C (KLK3-form) and Cathepsin D-cleaved form of
VEGF-C (CATD-form) were injected into the Tibialis anterior (TA) muscles of C57Bl/6JRccHsd (Envigo
Harlan) female mice. Mice were sacrificed 3 weeks after transduction and the tibialis muscles were
harvested. All animal experiments carried out in this study were performed according to guidelines
and regulations approved by the National Board for Animal Experiments of the Provincial State
Office of Southern Finland.
Histochemistry and immunofluorescence
Mouse tibialis anterior muscle samples were embedded into Tissue-Tek OCT and frozen in liquid
nitrogen-cooled isopentane. 10mm-sections were stained for the lymphatic marker Lyve-1
(Karkkainen et al., 2004, 1:1000) and blood vascular marker CD31 (BD Biosciences, San Jose, CA,
1:500), followed by Alexa-conjugated secondary antibodies (Molecular Probes/Thermo Fisher Scien-
tific). Nuclei were stained with DAPI with VECTASHIELD (Vector Laboratories, Burlingame, CA).
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Fluorescent images were obtained with an Axio Imager Z2 upright epifluorescence microscope (Carl
Zeiss AG, Oberkochen, Germany). Images were processed and analysed with Fiji ImageJ (NIH).
RNA extraction and quantitative real time PCR
Muscle tissues were lysed using Trisure reagent (Bioline, London, UK) and the RNA was extracted
with Nucleospin RNA II kit (Macherey-Nagel, Du¨ren, Germany). cDNA was synthesized with High-
Capacity cDNA Reverse Transcription Kits (Applied Biosystems/Thermo Fisher Scientific) using 1 mg
RNA. qRT-PCR was performed with SensiFast SYBR No-ROX Kit (Bioline). All data were normalized
to GAPDH. Relative gene expression levels were calculated using the 2-DDCt method. VEGF-C (fwd
5’-TGAACACCAGCACGAGCTAC-3’, rev 5’-TCGGCAGGAAGTGTGATTGG-3’) and mGAPDH (fwd
5’-ACAACTTTGGCATTGTGGAA-3’, rev 5’-GATGCAGGGATGATGTTCTG-3’) primers were used for
the real time PCR.
Statistical analysis
Data are presented as mean ± SD or mean ± SEM. Data were analysed using GraphPad Prism statis-
tical analysis software (Version 8). Data analysis details are mentioned in the respective figure
legends.
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